Stocks · News reference

Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60

Jul 22, 2026, 11:17 AMBenzinga Newsdesk

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 6:52 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
Read original at benzinga
CLDX
BenzingaAug 7, 2026, 10:50 AMBenzinga Newsdesk
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
Read original at benzinga
CLDX
BenzingaAug 6, 2026, 9:57 PMBenzinga Newsdesk
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Read original at benzinga
CLDX
BenzingaJul 29, 2026, 4:11 PMBenzinga Newsdesk
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Read original at benzinga
CLDX